All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear from you! 📣

(You can also reach out to me on LinkedIn)

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

THE GOOD
Business Development

Need a job? J.P. Morgan’s life science VC team is expanding
Biotech investing, venture capital - Read more [Paywall]

Tiba Biotech handed BARDA contract to develope swine flu vaccine
RNAi vaccine, pandemic response, H1N1, swine flu - Read more

THE GOOD
Clinical Trials

Pfizer pushes forward with their once-daily obesity pill, dose optimization studies in 2H 2024.
Small molecule, obesity, weight-loss - Read more

Faron Pharmaceuticals has a positive FDA meeting, suggests that Faron run a confirmatory Ph3 trial
Monoclonal antibody, myelodysplastic syndrome - Read more

THE GOOD
Fundraises

Element Biosciences in their element with a $277M Series D, further challenging Illumina’s DNA sequencing dominance
Instrumentation, DNA sequencing - Read more

Pan Cancer T €4.25M ($4.63M) Seed extension
TCR-T cell therapy, colorectal cancer, ovarian cancer - Read more

THE GOOD
Market Reports

Obesity meds set to dominate top drug rankings in the 2030s; report
GLP-1, obesity, weight-loss - Read more

THE GOOD
Partnerships

Ipsen signs licensing partnership with Foreseen Biotechnology, up to $1.03B in payments and biobucks
Antibody-drug conjugate, solid tumor, cancer - Read more

THE GOOD
Patient Access

CSL Seqirus, Sanofi, GSK begin shipping fall flu vaccine
Flu vaccine, influenza, flu season - Read more

THE GOOD
Politics & Policy

Bipartisan support passes “patent thicket” bill, preventing pharma from building patent barriers to biosimilar competition
Pharma patents, drug patents, biosimilar - Read more

THE GOOD
Research

Hear the good news; CRISPR gene therapy stops genetic progressive hearing loss in mice
CRISPR gene editing, gene therapy, hearing loss - Read more

THE GOOD
Strategic Plans

Eli Lilly coming for the Alzheimer’s crown after Kisunla’s FDA approval
Monoclonal antibody, Alzheimer’s - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Approvals & Labels

FDA follows their adcom recommendations, rejects Novo Nordisk’s once-weekly insulin application
Insulin, diabetes - Read more

THE BAD
Partnerships

Akebia Therapeutics ends kidney disease partnership with CSL Vifor, and sets high price for recently approved anemia med
Small molecule, chronic kidney disease, anemia - Read more

THE BAD
Strategic Plans

Novartis restructuring in San Diego, R&D site closure by end of 2025
Site closure, research & development - Read more

Cara Therapeutics begins the dreaded search for “strategic alternatives”
Small molecule, chronic kidney disease-associated pruritus - Read more

THE UGLY
Clinical Trials

Salarius Pharmaceuticals slapped with partial clinical hold by the FDA after a "serious and unexpected Grade 4 adverse event"
Small molecule, myelodysplastic syndromes, chronic myelomonocytic leukaemia, cancer - Read more

THE UGLY
Lawsuits

FTC to follow-up scathing Pharmacy Benefit Manager report with lawsuit over insulin prices
Drug prices, insulin - Read more

Abbvie doesn’t want to turn-over previously privileged attorney-client conversations
Testosterone, antitrust, generic - Read more 

THE UGLY
Politics & Policy

Medicaid is paying for TV-dinner style “medically tailored” meals that aren’t remotely healthy; report - Read more [Paywall]

THE UGLY
Research

A carcinogen at any dose; recent study elaborates link between alcohol consumption and cancer - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.